What is Transcripta Bio?
Transcripta Bio operates at the intersection of biotechnology and artificial intelligence, specializing in the application of transcriptomics to decode complex cellular responses to disease and pharmacological intervention. By leveraging advanced computational biology, the company maps the intricate interactions between drugs and cellular pathways, effectively reducing the time and cost associated with traditional drug development. Its platform is designed to identify high-potential therapeutic candidates with greater precision, positioning the firm as a key player in the next generation of precision medicine. The company's market position is bolstered by its ability to synthesize massive datasets into actionable insights, providing a competitive edge in the high-stakes landscape of drug discovery and development.
How much funding has Transcripta Bio raised?
Transcripta Bio has raised a total of $24M across 1 funding round:
Other Financing Round
$24M
Other Financing Round (2026): $24M with participation from JAZZ Venture Partners, BlueYard Capital, Omnimed, and Mayo Clinic
Key Investors in Transcripta Bio
JAZZ Venture Partners
JAZZ Venture Partners is a venture capital firm that invests in technologies aimed at enhancing human performance across various sectors, including healthcare, wellness, and consumer markets.
BlueYard Capital
BlueYard Capital is a venture capital firm that invests in innovative technologies across various sectors, including computation, engineering, biology, and cryptocurrency.
Omnimed
OMNIMED is a data platform company that offers the SmartOR autonomous monitoring platform, which utilizes AI to provide insights for administrative, clinical, and risk teams in operating rooms.
What's next for Transcripta Bio?
With this major enterprise-level funding, Transcripta Bio is poised to transition into a more aggressive phase of clinical validation and platform expansion. The strategic roadmap likely includes the scaling of its AI-driven models to encompass a broader range of therapeutic areas, potentially targeting complex diseases that have historically eluded traditional discovery methods. Furthermore, the company is expected to leverage its recent capital to strengthen its collaborative ecosystem, potentially forming new partnerships with global healthcare institutions to validate its findings in real-world clinical settings. As the firm continues to refine its computational architecture, the focus will remain on optimizing the transition from digital discovery to tangible medical breakthroughs, ensuring long-term value creation for stakeholders and patients alike.
See full Transcripta Bio company page
